Sugi Predict

Sugi Predict / Targets / ESR1

ESR1

Estrogen receptor · P03372 · ESR1 on Sugi Atlas →

728,313 patent compounds predicted against ESR1, 425,426 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Raloxifene Raloxifene (SCHEMBL6144) 1.00 20/20
Raloxifene Raloxifene (SCHEMBL19077) 1.00 20/20
Raloxifene Raloxifene (SCHEMBL19078) 0.96 20/20
Afimoxifene Afimoxifene (SCHEMBL9189) 1.00 14/20
Diethylstilbestrol Diethylstilbestrol (SCHEMBL9223) 1.00 14/20
Diethylstilbestrol Diethylstilbestrol (SCHEMBL9224) 1.00 14/20
Droloxifene Droloxifene (SCHEMBL4842) 0.82 13/20
Droloxifene Droloxifene (SCHEMBL4843) 0.82 13/20
Diethylstilbestrol Diethylstilbestrol (SCHEMBL9372) 0.78 13/20
Diethylstilbestrol Diethylstilbestrol (SCHEMBL9373) 0.67 13/20
Bisphenol A Bisphenol A (SCHEMBL15062) 1.00 12/20
Toremifene Toremifene (SCHEMBL7465) 0.91 12/20
Droloxifene Droloxifene (SCHEMBL4192) 0.87 12/20
Droloxifene Droloxifene (SCHEMBL4193) 0.87 12/20
SCHEMBL18750 SCHEMBL18750 0.80 12/20
SCHEMBL25881 SCHEMBL25881 0.58 12/20
SCHEMBL18139 SCHEMBL18139 0.43 12/20
SCHEMBL21027 SCHEMBL21027 1.00 11/20
SCHEMBL10141 SCHEMBL10141 0.59 11/20
SCHEMBL9371 SCHEMBL9371 0.53 11/20

Clinical trials — most relevant to ESR1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Selective Estrogen Receptor Modulators (SERMs) - A Potential Treatment for Psychotic Symptoms of Schizophrenia in Men? PHASE4COMPLETED
Fulvestrant in Metastatic Breast Cancer PHASE4UNKNOWN
Chronic Effects of Estrogen in Microcirculation PHASE4COMPLETED
Selective Estrogen Receptor Modulators - A Potential Treatment for Psychotic Symptoms of Schizophrenia PHASE4COMPLETED
Selective Estrogen Receptor Modulators for Women of Child-bearing Age With Schizophrenia PHASE4COMPLETED
Raloxifene as an Adjuvant Treatment of the Negative Symptoms of Schizophrenia in Post-menopausal Women PHASE3COMPLETED
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation PHASE3UNKNOWN
Overcoming Endocrine Resistance in Metastatic Breast Cancer PHASE3UNKNOWN
Phase 3 Trial of Elacestrant Versus Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer PHASE3COMPLETED
Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment in Genomically and/or Clinically High-risk ER+/HER2- eBC PHASE3RECRUITING
STUDY02001740;22SCH740: Estradiol For ER+ Advanced Breast Cancer (ESTHER) PHASE2RECRUITING
Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer PHASE2RECRUITING
PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA) PHASE2RECRUITING
Evaluating the Efficacy and Safety of Fulvestrant Plus DNA Damage Repair Inhibitors After a CDK4/6 Inhibitor PHASE2RECRUITING
The Use of Selective Estrogen Receptor Modulators in the Treatment of Schizophrenia- a Pilot Study PHASE2COMPLETED
Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation PHASE2COMPLETED
Oral CDB-4124 vs. Placebo in Stage I-II Primary Breast Cancer PHASE2UNKNOWN
Phase II Study of Neoadjuvant ArOMatase Inhibitor Therapy for ER+ Breast Cancer (NAOMI) PHASE2ACTIVE_NOT_RECRUITING
4FMFES-PET Imaging of Endometrial and Ovarian Cancers PHASE1/PHASE2COMPLETED
A Study to See Whether Estrogen Can Slow the Growth of Some ER Positive Breast Cancers PHASE2ACTIVE_NOT_RECRUITING
Immunologic Targeting of ESR1 Receptor for Hormone Receptor Expressing Metastatic Breast Cancer PHASE1RECRUITING
Monitoring luminAl Breast Cancer Through the Evaluation of Mutational and epiGeNEtic alteraTIons of Circulating ESR1 DNA nanUNKNOWN
Epithelioid Haemangioendothelioma Observational Study nanRECRUITING
Study of Tissue Samples From Women Treated With Paclitaxel for Breast Cancer on Clinical Trial CALGB-9344 or CALGB-9741 nanCOMPLETED
Genetic Study of CYP2D6 Enzyme and Therapeutic Drug Monitoring of Tamoxifen nanUNKNOWN
Clinical and Basic Research on the Necessity of Scar Tissue Resection During Intrauterine Adhesions nanUNKNOWN
Estrogen Receptor Gene Mutations nanCOMPLETED
Feasibility of Serial Multisite Image-guided Biopsy to Study Breast Cancer Evolution nanRECRUITING
21-gene in Elder Breast Cancer Patients With Lymph Node Metastasis nanRECRUITING
ESR1 Mutations in Asian ER+ Metastatic Breast Cancer on Hormonal Therapy-based Treatments nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a ESR1 binder may also engage these)

ProteinNameSimilarity
P06211 — 1.000 P06211 →
P19785 — 1.000 P19785 →
Q29040 — 1.000 Q29040 →
Q9TV98 — 1.000 Q9TV98 →
P49884 — 1.000 P49884 →
Q53AD2 — 1.000 Q53AD2 →
P06212 — 1.000 P06212 →
Q9XSB5 — 0.999 Q9XSB5 →
P50241 — 0.999 P50241 →
Q91250 — 0.999 Q91250 →
Q9TU15 — 0.999 Q9TU15 →
P16058 — 0.998 P16058 →
Q9QZJ5 — 0.997 Q9QZJ5 →
Q64249 — 0.997 Q64249 →
P57717 — 0.997 P57717 →
Q9YHZ7 — 0.997 Q9YHZ7 →
P81559 — 0.997 P81559 →
Q9W6M2 — 0.997 Q9W6M2 →
Q9XSW2 — 0.997 Q9XSW2 →
Q9YH33 — 0.997 Q9YH33 →
P50242 — 0.997 P50242 →
O42132 — 0.997 O42132 →
Q95171 — 0.997 Q95171 →
Q9PVZ9 — 0.996 Q9PVZ9 →
ESR2 Estrogen receptor beta 0.996 landscape →
O13012 — 0.996 O13012 →
Q9PVE2 — 0.995 Q9PVE2 →
Q62986 — 0.995 Q62986 →
Q9IAL9 — 0.995 Q9IAL9 →
O08537 — 0.995 O08537 →